High Tide pegs fiscal Q3 adj. EBITDA at $9.6M to $10.6M

Executive Summary

• High Tide Inc. has released preliminary guidance for its third fiscal quarter ended July 31, 2025, projecting record revenue, adjusted EBITDA ahead of analyst forecasts, and a two-year high in same-store sales growth.
• The company anticipates a 7.4% increase in same-store sales, driven by momentum in its core Canadian business and its recent entry into the German market via the acquisition of a majority stake in Remexian Pharma GmbH.
• Full financial and operational results for Q3 2025 will be released on September 15, 2025, after market close, followed by a webcast and conference call on September 16, 2025.

Key Details

• Q3 2025 Financial Guidance:
  • Revenue: Expected to be at record levels.
  • Adjusted EBITDA: Projected to be ahead of analyst forecasts.
  • Same-Store Sales Growth: Anticipated to increase by 7.4%, marking the fastest growth rate in two years.
• Strategic Context:
  • CEO Raj Grover highlighted the strength of the core Canadian business and the strategic expansion into Germany through the acquisition of a majority stake in Remexian Pharma GmbH.
• Earnings Event Schedule:
  • Results Release Date: Monday, September 15, 2025, after markets close.
  • Webcast/Conference Call Date: Tuesday, September 16, 2025, at 11:30 a.m. Eastern Time.
  • Access Information:
    • North American toll-free: 1-888-510-2154
    • International toll-free (Germany): 498005889782
  • Replay: Available three hours after the live webcast.

Notable Quotes

• "This quarter's guidance showcases the strength and momentum of High Tide like never before. We expect to deliver record revenue and powerful sequential adjusted EBITDA growth. These results have been fuelled by a projected 7.4-per-cent increase in same-store sales during the quarter, which was our fastest growth rate in two years," said Raj Grover, founder and chief executive officer of High Tide.
• "These results, anticipated to be well above analyst expectations, highlight how underappreciated our core Canadian business remains. With our entry into Germany, through the recently announced acquisition of a majority stake in Remexian Pharma GmbH, we're no longer just a Canadian success story -- we're building the next global cannabis powerhouse."